- Tytuł:
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology July 2021 22(7):931-945
Czasopismo naukowe